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Abstract Previously, we have shown that epidermal
growth factor receptor (EGFR)-selective delivery of soluble
tumor necrosis factor-related apoptosis-inducing ligand
(sTRAIL), by genetic fusion to antibody fragment scFv425,
enhances the tumor-selective pro-apoptotic activity of
sTRAIL. Insight into the respective contribution of the
agonistic receptors TRAIL-R1 and TRAIL-R2 to TRAIL-
induced apoptosis may provide a rational approach to
further optimize TRAIL-based therapy. Recently, this issue
has been investigated using sTRAIL mutants designed to
selectively bind to either receptor. However, the relative
contribution of the respective TRAIL receptors, in partic-
ular TRAIL-R1, in TRAIL signaling is still unresolved.
Here, we fused scFv425 to designed sTRAIL mutant
sTRAILmR1–5, reported to selectively activate TRAIL-
R1, and investigated the therapeutic apoptotic activity of
this novel fusion protein. EGFR-specific binding of
scFv425:sTRAILmR1–5 potently induced apoptosis, which
was superior to the apoptotic activity of scFv425:sTRAILwt
and a nontargeted MOCK-scFv:sTRAILmR1–5. During co-
treatment with cisplatin or the histone deacetylase inhibitor
valproic acid, scFv425:sTRAILmR1–5 retained its superior
pro-apoptotic activity compared to scFv425:sTRAILwt.
However, in catching-type Enzyme-Linked Immuno-
Sorbent Assays with TRAIL-R1:Fc and TRAIL-R2:Fc,
scFv425:sTRAILmR1–5 was found to not only bind to
TRAIL-R1 but also to TRAIL-R2. Binding to TRAIL-R2
also had functional consequences because the apoptotic
activity of scFv425:sTRAILmR1–5 was strongly inhibited
by a TRAIL-R2 blocking monoclonal antibody. Moreover,
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ligands for cancer therapy.scFv425:sTRAILmR1–5 retained apoptotic activity upon
selective knockdown of TRAIL-R1 using small inhibitory
RNA. Collectively, these data indicate that both agonistic
TRAIL receptors are functionally involved in TRAIL
signaling by scFv425:sTRAILmR1–5 in solid tumor cells.
Moreover, the superior target cell-restricted apoptotic
activity of scFv425:sTRAILmR1–5 indicates its therapeutic
potential for EGFR-positive solid tumors.
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Introduction
The Tumor Necrosis Factor-Related Apoptosis-Inducing
Ligand (TRAIL) is normally present as a type II transmem-
brane protein on immune effector cells, such as natural killer
(NK) cells. As such, TRAIL is involved in the elimination of,
e.g., metastasizing cancer cells [1, 2]. TRAIL can also be
proteolytically cleaved into a homotrimeric soluble form,
soluble TRAIL (sTRAIL), that partly retains tumoricidal
activity [3, 4]. Several recombinant derivatives of sTRAIL
have been generated that all display promising antitumor
activity in vitro and in human xenografted tumor mouse
models [5–7].
Recently, we and others have demonstrated that the
tumor cell specific activity of sTRAIL can be augmented by
genetic fusion to a tumor-selective antibody fragment [8–
12]. Antibody fragment-mediated binding of such scFv:
sTRAIL fusion proteins to a cell surface-expressed target
antigen results in tumor cell accretion and converts soluble
TRAIL into membrane-bound TRAIL. Subsequently, ago-
nistic TRAIL receptors are efficiently activated in a
monocellular and/or bicellular manner.
TRAIL signals apoptosis by binding to the agonistic
receptorsTRAIL-R1andTRAIL-R2[13–15]. Concomitantly,
an intracellular cascade of caspase activation ensues that
ultimately results in the apoptotic demise of the cell. These
agonistic receptors are characterized by a cytoplasmic region
known as the Death Domain, which is critical for signal
transduction upon TRAIL-binding. TRAIL can also interact
with three antagonistic receptors, TRAIL-R3, TRAIL-R4,
and osteoprotegerin. TRAIL-R3 is a phospholipid-anchored
receptor that lacks a cytoplasmic domain [14, 16, 17].
TRAIL-R4 has a truncated intracellular domain incapable of
transmitting the apoptotic signal [18–20]. Osteoprotegerin is
a soluble receptor for TRAIL [21]t h a ti sb e s tk n o w nf o ri t s
involvement in bone homeostasis as a soluble receptor for
the tumor necrosis factor homolog Receptor Activator for
Nuclear Factor κ B Ligand (RANKL).
This intricate receptor system, with five distinct recep-
tors that differentially bind and interact with TRAIL,
suggests that the outcome of TRAIL signaling is subject
to a high degree of regulation [22]. Therefore, insight into
the respective contribution of the agonistic receptors
TRAIL-R1 and TRAIL-R2 to apoptotic signaling by
TRAIL may provide a rational approach to optimize
TRAIL therapy for a specific tumor type.
Several laboratories have studied this issue using
sTRAIL mutants designed to selectively bind to one of
the agonistic TRAIL receptors and not to the antagonistic
receptors [23–25]. Using TRAIL-R1 and TRAIL-R2
selective sTRAIL mutants, Kelley et al. ascribed a greater
contribution of TRAIL-R2 to TRAIL-apoptotic signaling in
solid tumor cells [23]. Similarly, van der Molen et al.
reported that selective TRAIL-R2 activation results in
enhanced pro-apoptotic activity [24]. On the other hand,
MacFarlane et al. concluded that apoptosis signaling was
exclusively mediated by TRAIL-R1 in Chronic Lympho-
cytic Leukemia [25]. Importantly, experimental data in the
latter paper indicates that the TRAIL-R1 selective sTRAIL
mutant used by Kelley et al. is actually largely inactive.
Thus, the exact contribution of TRAIL-R1 and TRAIL-R2
to TRAIL-induced apoptosis remains to be elucidated.
Previously, we have demonstrated that epidermal growth
factor receptor (EGFR)-targeted delivery of wild-type
sTRAIL, using scFv425:sTRAIL, enhanced the tumor-
selective binding and activity [10]. Here, we genetically
fused antibody fragment scFv425 to sTRAILmR1–5
reported by MacFarlane et al. to selectively activate
TRAIL-R1 and investigated the therapeutic apoptotic
activity of this novel fusion protein. Fusion protein
scFv425:sTRAILmR1–5 showed superior apoptotic activity
compared to the corresponding wild-type sTRAIL fusion
protein on half of the EGFR-positive solid tumor cell lines
tested and showed a nonsignificant trend to higher
apoptotic activity on the other cell lines. Furthermore,
scFv425:sTRAILmR1–5 showed superior apoptotic activity
in comparison to a MOCK-scFv:sTRAILmR1–5 fusion
protein, with irrelevant target specificity. However, in
contrast to the findings of MacFarlane et al., we found that
the sTRAILmR1–5 domain in our scFv425:sTRAILmR1–5
fusion protein also bound to and partly signaled apoptosis via
TRAIL-R2. Taken together, EGFR-selective delivery and
induction of apoptosis by scFv425:sTRAILmR1–5i sa
potentiallypromisingtherapeuticapproachforEGFR-positive
solid tumors.
Materials and methods
Cell lines
The following cell lines were purchased from the American
Type Culture Collection (Manassas, VA, USA): ALL T-cell
910 J Mol Med (2008) 86:909–924line (Jurkat), Burkitt Lymphoma (Ramos), epidermoid
carcinoma (A431), ovarian carcinoma (OVCAR-3), colon
carcinoma (WiDr and HT-29), lung carcinoma (A549), renal
cell carcinoma (Sk-rc-52), prostate carcinoma (PC-3M),
glioblastoma multiforme (A172), and medulloblastoma
(HS-683). Jurkat.EGFRvIII was generated as previously
described [10]. Renal cell carcinomas (RC21 cells) were
generously provided by Prof. Dr. Clemens Löwik (Univer-
sity Medical Center Leiden, Leiden, The Netherlands). All
cell lines were cultured at 37°C in a humidified 5% CO2
atmosphere. All cell lines were cultured in RPMI 1640
(Cambrex Bio Science, Verviers, France) supplemented with
10% fetal calf serum.
Expression of EGFR and TRAIL receptors
Membrane expression levels of EGFR were analyzed using
mAb425. Membrane expression levels of TRAIL receptors
1, 2, 3, and 4, were analyzed by flow cytometry using a
TRAIL receptor antibody kit purchased from Alexis (10P’s,
Breda, The Netherlands). Briefly, cells were harvested,
washed using serum-free RPMI, and resuspended in 100 μl
fresh medium containing the appropriate primary monoclonal
antibody (mAb). Specific binding of the primary antibody
was detected using a phycoerythrin (PE)-conjugated second-
ary antibody (DAKO, Glostrup, Denmark). All antibody
incubations were performed at 0°C for 45 min and were
followed by two washes with serum-free medium.
Recombinant sTRAIL, monoclonal antibodies,
and inhibitors
Flag-tagged sTRAIL and secondarily cross linked killer
TRAIL (kTRAIL) were both purchased from Alexis. MAb
425 (kindly provided by Merck, Darmstadt, Germany) is a
murine immunoglobulin G2a with high binding affinity for
the extracellular domain of EGFR and EGFRvIII. TRAIL-
neutralizing mAb 2E5 was purchased from Alexis (10P’s,
Breda, The Netherlands). MAb 425 competes with scFv425
for binding to the same epitope. The histone deacetylase
inhibitor valproic acid (VPA) was from Sigma–Aldrich
(Zwijndrecht, The Netherlands) and was dissolved at
100mMindH2O. The cytostatic drug cisplatin was dissolved
at 1 mg/ml in 0.9% NaCl. IκB kinase (IKK) inhibitor
wedelolactone was purchased from Sigma–Aldrich and
dissolved at 5 mM in DMSO. Caspase inhibitors zIETD-
FMK, zLEHD-FMK, and zVAD-FMK were purchased from
Calbiochem (VWR International B.V., Amsterdam, The
Netherlands) and dissolved at 10 mM in DMSO. Final
working concentrations of cisplatin, VPA, caspase inhibitors,
and wedelolactone were diluted in standard medium.
Production of scFv:sTRAIL fusion proteins
scFv425:sTRAILwt, scFv425:sTRAILmR1–5, and
MOCK-scFv:sTRAILmR1–5, targeted at the B-cell marker
CD20, were constructed and produced essentially as
described previously using expression vector pEE14 [10].
This plasmid encodes an N-terminal hemagglutinin (HA)
tag upstream of two multiple cloning sites (MCS). In the
first MCS, the high-affinity antibody fragment scFv425
(Vh-(G4S)3-Vl format) [26] was directionally inserted
using the unique SfiIa n dNotI restriction enzyme sites.
Alternatively, the upstream MCS of pEE14 was used to
insert DNA fragment scFvCD20. The synthetic DNA
sequence encoding scFvCD20 was generated by splice
overhang extension polymerase chain reaction (PCR)
technology using published sequence data of the heavy
chain (VH) and light chain (VL) domains of the murine
anti-CD20 mAb 2B8. The VH and VL sequences were
genetically linked via a flexible peptide linker ((GGGGS)3).
Moreover, restriction enzyme sites SfiI (GGCCCAGCCGG)
and NotI (GCGGCCGC) were added to the 5′-end and 3′-
end of the sequence, yielding a 756-bp DNA fragment. In
the second MCS, a PCR-truncated 593-bp DNA fragment
encodingtheextracellulardomainofhumanTRAIL(sTRAIL)
was cloned in frame using restriction enzymes XhoI and
HindIII, yielding plasmid pEE14-scFv425:sTRAILwt. Alter-
natively, the cDNA encoding sTRAILmR1–5 was inserted in
the second MCS. This sTRAIL mutant encodes five amino
acid substitutions compared to sTRAIL-wt [25] (see Table 1).
The resultant expression vectors were transfected into CHO-
K1 cells using Fugene 6 reagent (Roche Diagnostics, Almere,
The Netherlands) according to manufacturer’s instructions.
Transfectants were selected by the glutamine synthetase
system as described [27]. Single-cell sorting using the MoFlo
high speed cell sorter (Cytomation, Fort Collins, CO, USA)
established clones of scFv425:sTRAILwt, stably secreting
2.1μg/ml,scFv425:sTRAILmR1–5, stably secreting 2.7 μg/ml
and MOCK-scFv:sTRAILmR1–5, stably secreting 2.3 μg/ml.
Table 1 Changes in amino acid sequence of the sTRAIL domain of scFv425:sTRAILmR1–5 compared to scFv425:sTRAILwt
Amino acid pos. 189 191 193 199 201 213 215 264 266 267
scFv425:sTRAILwt Tyr Arg Gln Asn Lys Tyr Ser His Ile Asp
scFv425:sTRAIL-mR1 Tyr Arg Ser Val Arg Trp Asp His Ile Asp
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TRAIL receptor binding selectivity of scFv425:sTRAILwt
and scFv425:sTRAILmR1–5 was investigated with a
catching-type Enzyme-Linked ImmunoSorbent Assay
(ELISA) with either TRAIL-R1:Fc or TRAIL-R2:Fc (both
from Alexis, 10P’s BVBA) coated to the plates. Briefly,
maxisorb ELISA plates were coated overnight with 1 μg/ml
TRAIL-R1:Fc or TRAIL-R2:Fc, blocked with phosphate-
buffered saline (PBS), 0.1% Tween, or 3% Bovine Serum
Albumine (Sigma), washed twice with PBS and 0.1%
Tween, and incubated for 3 h with scFv425:sTRAILwt and
scFv425:sTRAILmR1–5, respectively. Specific binding was
assessed by staining for the N-terminal hemagglutinin tag
using Horseradish Peroxidase-conjugated anti-HA antibody
(Roche). Specific binding was visualized using 3,3′,5,5′-
Tetramethylbenzidine (Sigma) and measured using an
ELISA plate reader at OD450. Where indicated, incubation
with scFv425:sTRAILwt or scFv425:sTRAILmR1–5 was
performed in the presence of soluble TRAIL-R1:Fc, TRAIL-
R2:Fc, or Flag-tagged sTRAIL.
EGFR-specific binding of scFv425:sTRAIL fusion proteins
EGFR-specific binding of scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 was assessed by flow cytometry
using the EGFR-positive tumor cell line Jurkat.EGFRvIII.
In short, 1 × 10
6 cells were incubated with fusion protein
(300 ng/ml). Specific binding was detected using PE-
conjugated anti-TRAIL mAb B-S23 (Diaclone SAS,
Besançon, France) and subsequent fluorescent-activated
cell sorting analysis using a Calibur flow cytometer (Beck-
man Coulter, Mijdrecht, The Netherlands). Incubations
were carried out for 45 min at 0°C and were followed by
two washes with serum-free medium.
EGFR-restricted induction of apoptosis by scFv425:
sTRAIL fusion proteins
EGFR-restricted induction of apoptosis by the scFv425:
sTRAIL fusion proteins was assessed by loss of mitochon-
drial membrane potential (ΔΨ)o rb yc r y s t a lv i o l e t
cytotoxicity assay as described in more detail below. Where
indicated, treatment with scFv425:sTRAIL fusion proteins
or the MOCK-scFv:sTRAILmR1–5 was performed in the
presence or absence of mAb 425 (3 μg/ml) or mAb 2E5
(1 μg/ml). Loss of mitochondrial membrane potential
(ΔΨ): ΔΨ was analyzed using the stain DiOC6 (Eugene,
The Netherlands) as previously described [10]. Briefly,
cells were precultured in a 48-well plate at a concentration
of 0.3 × 10
5 cells/well. Subsequently, cells were treated for
16 h with the various experimental conditions, after which
cells were harvested and incubated for 20 min with DiOC6
(0,1 μM) at 37°C, harvested (1,000 g, 5 min), resuspended in
PBS,and assessed for staining by flow cytometry.Cell viability
assessed by crystal violet cytotoxicity assay:c e l l sw e r e
precultured in a 96-well plate at a concentration of 0.3 ×
10
5 cells/well. Subsequently, cells were treated for 16 h with
the various experimental conditions in a final volume of
200 μl. Cell viability was determined by crystal violet staining
(Sigma, Germany) as described previously [8]. Experimental
apoptosis induction was quantified as the percentage of
apoptosis induction compared to medium control. Each
experimental condition consisted of six independent wells.
Luminescent assay for caspase-8, caspase-9, and caspase-3 or
caspase-7 activity: caspase activity was assessed using
Caspase-Glo® 8 Assay, Caspase-Glo® 9 Assay, and Caspase-
Glo® 3 or 7 Assay according to manufacturer’s instructions
(Promega Benelux BV, Leiden, The Netherlands). The assays
are based on the cleavage of nonluminescent substrates by
activated caspases into a luminescent product. Luminescence
is quantified using an ELISA plate reader.
Immunoblot analysis of caspase-8, cFLIPL, and NFκB
Cells were seeded in 6-well plates at a final concentration
of 2.0 × 10
6 cells/ml and treated as indicated. Cell lysates
were prepared and immunoblot analysis was performed
essentially as described before [26]. Antibodies used were
anti-caspase-8 (Cell signaling technology, Beverly, MA,
USA), anti-cFLIPL clone NF6 (Alexis), NFκB p100/p52,
NFκB p105/p50, NFκB p65 (all from Santa-Cruz; Tebu-
Bio, Heerhugowaard, The Netherlands). Appropriate sec-
ondary peroxidase-conjugated antibodies were from DAKO
Cytomation (Glostrup, Denmark).
Selective knockdown of TRAIL-R1 or TRAIL-R2
using small inhibitory (si)RNA
OVCAR-3 cells were precultured in 6-well plates to 60%
confluency, after which, cells were treated with 10pM
TRAIL-R1 siRNA (sense: 5′-CACCAAUGCUUCCAA
CAAU-3′;a n t i s e n s e :5 ′-AUUGUUGGAAGCAUUGGU-3′)
or TRAIL-R2 siRNA (sense:5′-GACCCUUGUGCUCGUU
GUC-3′;a n t i s e n s e :5 ′-GACAACGAGCACAAGGGUC-3′;
Eurogentec S.A., Liege, Belgium). Treated cells were
cultured for 3 days, after which, selective TRAIL receptor
downregulation was verified by flow cytometry. Subsequent-
ly, cellswereplatedina48-wellplateat3×10
4 cells/well and
treated with scFv425:sTRAILwt, scFv425:sTRAILmR1–5,
agonistic TRAIL-R1 mAb, or agonistic TRAIL-R2 mAb.
Apoptosis was assessed by Δψ. For siRNA apoptosis
experiments, the experimental apoptosis was calculated
using the following formula: experimental apoptosis =
(specific apoptosis − spontaneous apoptosis)/(100 − sponta-
neous apoptosis) × 100%.
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fusion proteins and conventional and experimental
therapeutic drugs
Cells were plated at 3.0 × 10
4 cells/well in a 48-well plate
and allowed to adhere overnight. Subsequently, cells were
concurrently treated for 24h with scFv425:sTRAILwt or
scFv425:sTRAILmR1–5 with or without cisplatin or
histone deacetylase inhibitor VPA. Additive or synergistic
apoptotic effects were determined using the cooperativity
index (CI). CI was determined with the following formula:
the sum of apoptosis induced by single-agent treatment
divided by apoptosis induced by combination treatment.
When CI < 0.9, treatment was termed synergistic; when
0.9 < CI < 1.1, treatment was termed additive; when CI >
1.1, treatment was termed antagonistic.
IL-8 ELISA
To determine IL-8 productioninresponse to scFv425:sTRAILwt
and scFv425:sTRAILmR1–5, RC21, PC3-M, HT-29,
A549, and WiDr cells were treated with 850 ng/ml
fusion protein in the presence or absence of total caspase
inhibitor zVAD-FMK. After 16 h, supernatants were
analyzed for IL-8 levels using IL-8 ELISA according to
manufacturer’s protocol (Sanquin reagents, Amsterdam,
The Netherlands).
Statistical analysis
Data reported are mean values + standard error of the mean
of at least three independent experiments. Where appropri-
ate, statistical analysis was performed using two-sided,
unpaired Student’ s t-test. For all statistical analyses, a
statistically significant difference was defined as p < 0.05.
Results
EGFR-selective binding and induction of apoptosis
by scFv425:sTRAILwt and scFv425:sTRAILmR1–5
To determine whether the sTRAILmR1–5 domain of
scFv425:sTRAILmR1–5 had any influence on EGFR-
specific binding compared to scFv425:sTRAILwt, Jurkat.
EGFRvIII cells were incubated with scFv425:sTRAILwt
and scFv425:sTRAIL-mR1 and assessed for EGFR-specific
binding (Fig. 1a). As expected, both fusion proteins pos-
sessed identical binding characteristics to Jurkat.EGFRvIII
(Fig. 1a). Binding was EGFR-specific because pre-incuba-
tion with parental EGFR-blocking mAb 425 specifically
inhibited the binding of both scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 (data not shown).
To determine whether scFv425:sTRAILmR1–5, similar
to scFv425:sTRAILwt, showed EGFR-restricted apoptotic
activity, EGFR-positive RC21 cells were treated with
350 ng/ml scFv425:sTRAILwt and scFv425:sTRAILmR1–5.
Both fusion proteins potently induced apoptosis in RC21
cells (Fig. 1b). Importantly, induction of apoptosis by
scFv425:sTRAILwt and scFv425:sTRAILmR1–5i n
RC21 cells was specifically inhibited by co-incubation
with molar excess of parental EGFR-blocking mAb 425
(Fig. 1b). Thus, scFv425:sTRAILmR1–5 selectively binds
to EGFR, after which, apoptosis is induced by TRAIL
receptor crosslinking.
Subsequently, we determined whether the EGFR-selective
accretion of sTRAILmR1–5 to the cell surface of tumor cells
resulted in enhanced apoptotic activity compared to non-
targeted sTRAILmR1–5. To this end, EGFR-positive cells
were treated with scFv425:sTRAILmR1–5 and a MOCK-
scFv:sTRAILmR1–5 fusion protein containing an scFv anti-
body fragment of irrelevant specificity targeted at the B-cell
marker CD20. Dose escalation experiments, exemplified here
for PC-3M (Fig. 1c), identified that scFv425:sTRAILmR1–5
showed superior apoptotic activity compared to MOCK-scFv:
sTRAILmR1–5 in PC-3M, A431, and RC21 cells (Fig. 1d).
Thus, EGFR-selective binding results in superior apoptotic
activity of scFv425:sTRAILmR1–5c o m p a r e dt ot h e
nontargeted soluble MOCK-scFv:sTRAILmR1–5.
scFv425:sTRAILmR1–5 has superior apoptotic activity
on a subset of EGFR-positive solid tumor cell lines
ToevaluatetheapoptoticactivityofscFv425:sTRAILmR1–5,
we tested a panel of ten EGFR-positive tumor cell lines
with scFv425:sTRAILmR1–5 and scFv425:sTRAILwt.
Dose escalation experiments, exemplified here with PC-3M
cells (Fig. 2a), identified that scFv425:sTRAILmR1–5h a d
superior apoptotic activity compared to scFv425:sTRAILwt
in OVCAR-3, A549, HT-29, HS-683, A431, and PC-3M
cells (Fig. 2aa n dba n dS u p p l e m e n t a r yF i g .1). Dose
escalation experiments, exemplified here for RC21
(Fig. 2c), on RC21, WiDr, Sk-rc-52, and A172 identified no
significant difference in apoptotic activity (Fig. 2da n d
Supplementary Fig. 2). Of note, in the latter cell lines,
scFv425:sTRAILmR1–5 consistently showed a nonsignifi-
cant trend toward higher apoptotic activity compared to
scFv425:sTRAILwt.
TodeterminewhetherscFv425:sTRAILmR1–5re ta in edit s
superior apoptotic activity compared to scFv425:sTRAILwt
upon cotreatment with other conventional or experimental
anticancer therapeutics, OVCAR-3 cells were treated with the
respective fusion proteins alone or in combination with VPA
or cisplatin (Fig. 2e and f). Importantly, cotreatment with
cisplatin and VPA synergistically enhanced the apoptotic
activity of both scFv425:sTRAILwt (CI of 0.73 and 0.42,
J Mol Med (2008) 86:909–924 913respectively) and scFv425:sTRAILmR1–5 (CI of 0.57 and
0.42, respectively). However, the scFv425:sTRAILmR1–5
fusion protein retained a significantly higher pro-apoptotic
activity compared to scFv425:sTRAILwt (p < 0.001 and p <
0.05, respectively). The synergistic effect of cotreatment with
VPA and cisplatin was still fully dependent on EGFR-
selective binding of the respective fusion protein because
cotreatment with EGFR-blocking mAb 425 abrogated the
induction of apoptosis (data not shown).
The apoptotic activity of scF425:sTRAILwt
and scFv425:sTRAILmR1–5 does not correlate
with EGFR- or TRAIL receptor expression
Because the sTRAILmR1–5 domain was described to be
selective for TRAIL-R1, we subsequently analyzed whether
the differences in apoptotic activity of scFv425:sTRAILwt
and scFv425:sTRAILmR1–5 in the subset of cell lines was
due to differential TRAIL receptor expression. To this end,
we determined the relative TRAIL receptor expression
levels of the cell lines as well as the expression level of EGFR
(Table 2). In agreement with our previous findings for
scFv425:sTRAILwt, the activity of scFv425:sTRAILmR1–5
did not correlate with the level of EGFR expression.
Importantly, there was also no correlation between the
expression levels of TRAIL-R1, TRAIL-R2, or TRAIL-R4
and the apoptotic activity of the fusion proteins. In
addition, there was not a clear correlation between the
various ratios of TRAIL-R2/TRAIL-R1, TRAIL-R1/
TRAIL-R4, or TRAIL-R2/TRAIL-R4, although four out
of the six (66%) cell lines that were significantly more
sensitive to scFv425:sTRAILmR1–5 appeared to have a
more balanced TRAIL-R2/TRAIL-R1 ratio, in compari-
son to two out of four (50%) of the other cell lines. A
particularly intriguing finding is the fact that some of the
cell lines, most sensitive to scFv425:sTRAILmR1–5,
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Fig. 1 EGFR-selective binding
and induction of apoptosis by
scFv425:sTRAILwt and
scFv425:sTRAILmR1–5. a
Jurkat.EGFRvIII cells were
incubated with PE-conjugated
anti-TRAIL mAb B-S23 (solid
fill), scFv425:sTRAILwt + mAb
B-S23 (solid line), or
scFv425:sTRAILmR1–5 + mAb
B-S23 (dotted line), after which
specific binding was assessed
by flow cytometry. b EGFR-
positive RC21 cells were
treated with 350 ng/ml
scFv425:sTRAILwt or
scFv425:sTRAILmR1–5 in the
absence or presence of parental
EGFR-blocking mAb 425. c
PC-3M cells were treated for
16 h with increasing concentra-
tions of scFv425:sTRAILmR1–5
or the nontargeted
MOCK-scFv:sTRAILmR1–5. d
EGFR-positive cell lines
PC-3M, A431, and RC21 were
treated with 850 ng/ml
scFv425:sTRAILmR1–5o r
MOCK-scFv:sTRAILmR1–5.
Apoptosis was assessed by ΔΨ.
**p<0.001, ***p<0.0001
914 J Mol Med (2008) 86:909–924have a very low expression of TRAIL-R1 (Table 2,H T 2 9 ;
MFI of 8.1, HS683; MFI of 0.5, PC-3M; MFI of 1.9).
scFv425:sTRAILwt but also scFv425:sTRAILmR1–5 binds
to both TRAIL-R1 and TRAIL-R2
The sTRAILmR1–5 mutant we genetically fused to scFv425
was reported by MacFarlane et al. to selectively activate TRAIL-
R1. However, we found no clear correlation between the
TRAIL-R1status andactivityof scFv425:TRAILmR1–5; within
certain cell lines, very low TRAIL-R1 expression coincided with
high apoptotic activity of scFv425:sTRAILmR1–5. Therefore,
we performed a catching-type ELISA, in which plates were
coated either with TRAIL-R1:Fc or TRAIL-R2:Fc, to assess
whether the sTRAILmR1–5 domain was indeed selective for
TRAIL-R1. As expected, binding of scFv425:sTRAILwt was
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Fig. 2 Fusion protein
scFv425:sTRAILmR1–5 has
superior apoptotic activity on a
subset of EGFR-positive solid
tumor cell lines. a Dose-
response curve of induction of
apoptosis in PC-3M cells by
increasing concentrations of
scFv425:sTRAILwt or
scFv425:sTRAILmR1–5. b
OVCAR-3, A549, HT-29,
HS-683, A431, and PC-3M
cells were treated with
scFv425:sTRAILwt (850 ng/ml)
or scFv425:sTRAILmR1–5
(850 ng/ml). Cell viability in
HS-683 was assessed by crystal
violet toxicity assay. c Dose-
response curve of apoptosis
induction in RC21 cells treated
with increasing concentrations
of scFv425:sTRAILwt or
scFv425:sTRAILmR1–5.
d RC21, WiDr, Sk-rc-52, and
A172 cells were treated
with scFv425:sTRAILwt
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(850 ng/ml). e OVCAR-3 cells
were treated alone or with a
combination of the HDACi
VPA (2 mM) and
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(350 ng/ml). f OVCAR-3 cells
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(350 ng/ml). Unless indicated
otherwise, apoptosis was
assessed by ΔΨ.* p<0.05,
**p<0.001, ***p<0.0001
J Mol Med (2008) 86:909–924 915observed in both TRAIL-R1:Fc and TRAIL-R2:Fc coated
plates (Fig. 3a and b, open squares). Surprisingly, however,
scFv425:sTRAILmR1–5a l s op r o v e dt ob i n dt ob o t hT R A I L -
R1:Fc and TRAIL-R2:Fc (Fig. 3a and b, open triangles).
To establish whether this interaction was indeed specific,
we competitively inhibited the binding of scFv425:sTRAILwt
and scFv425:sTRAILmR1–5, as observed in the TRAIL-R1:
Fc ELISA, using soluble TRAIL-R1:Fc and TRAIL-R2:Fc
(Fig. 3c and d). Importantly, binding of both fusion proteins
was competitively inhibited by TRAIL-R1:Fc and TRAIL-
R2:Fc (Fig. 3c and d). Of note, whereas scFv425:sTRAILwt
binding was more efficiently inhibited by addition of
TRAIL-R2:Fc, binding of scFv425:sTRAIL-mR1–5w a s
more efficiently inhibited by TRAIL-R1:Fc. Thus,
scFv425:sTRAILmR1–5 appears to preferentially bind to
TRAIL-R1, whereas scFv425:sTRAILwt appears to pref-
erentially bind to TRAIL-R2. In addition, binding of
scFv425:sTRAILwt and scFv425:sTRAIL-mR1–5t o
TRAIL-R1:Fc was competitively inhibited by Flag-tagged
wild-type sTRAIL (Fig. 3e). Together, these results clearly
show that scFv425:sTRAILmR1–5 specifically binds to not
only TRAIL-R1 but also TRAIL-R2.
scFv425:sTRAILwt but also scFv425:sTRAILmR1–5
activate apoptosis via both TRAIL-R1 and TRAIL-R2
To determine whether binding of scFv425:sTRAILmR1–5
to TRAIL-R2 also had functional consequences, RC21
renal cancer cells (TRAIL-R1
+/R2
+) were treated with
scFv425:sTRAILmR1–5 in the presence of TRAIL-R1
blocking mAb, TRAIL-R2 blocking mAb, or a combination
of both mAbs. Importantly, induction of apoptosis by
scFv425:sTRAILmR1–5 in RC21 cells was significantly
inhibited not only by TRAIL-R1 mAb but also by the
TRAIL-R2 mAb (Fig. 4a). Of note, the TRAIL-R2 mAb
was even more effective than the TRAIL-R1 mAb in
blocking scFv425:sTRAILmR1–5 activity. Cotreatment
with both blocking mAbs abrogated the apoptotic activity
of scFv425:sTRAILmR1–5. Similar results were obtained
for scFv425:sTRAILwt (Fig. 4b) as well as kTRAIL
(Fig. 4c), an artificially cross linked sTRAIL preparation.
However, compared to the scFv425:sTRAILmR1–5 fusion
protein, both scFv425:sTRAILwt as well as kTRAIL were
far less efficiently blocked by TRAIL-R1 mAb, TRAIL-R2
mAb, or the combination of both mAbs.
In addition, treatment of RC21 cells with scFv425:
sTRAILmR1–5 in the presence of TRAIL-R1:Fc or TRAIL-
R2:Fc potently inhibited the induction of apoptosis (Fig. 4d).
Of note, TRAIL-R2:Fc was more efficient than TRAIL-R1:
Fc in blocking apoptosis. Similarly, TRAIL-R1:Fc and
TRAIL-R2:Fc also inhibited the apoptotic activity of
scFv425:sTRAILwt and kTRAIL (Fig. 4d) although, again,
to a lesser extent than scFv425:sTRAILmR1–5.
To further verify that both TRAIL-R1 and TRAIL-R2
signalingareinvolvedinactivationofapoptosisinsolidtumor
cells by scFv425:sTRAILwt and scFv425:sTRAILmR1–5,
siRNA-mediated knockdown of TRAIL-R1 or TRAIL-R2
wasperformedinOVCAR-3cells.Normally,OVCAR-3cells
express TRAIL-R1 and TRAIL-R2 at approximately equal
levelson the cellsurface (Fig. 5a). In addition, treatment with
scFv425:sTRAILwt and scFv425:sTRAILmR1–5p o t e n t l y
activates apoptosis (Fig. 5b). Treatment of OVCAR-3 cells
with TRAIL-R1 specific siRNA resulted in ~92% down-
regulation of TRAIL-R1 (Fig. 5c). Similarly, treatment with
TRAIL-R2 specific siRNA resulted in ~91% downregulation
of TRAIL-R2 (Fig. 5d).
The absence of TRAIL-R1 or TRAIL-R2 signaling upon
siRNA treatment was confirmed using TRAIL receptor
Table 2 EGFR/TRAIL receptor expression and the correlation with the apoptotic activity of scFv425:sTRAILwt/scFv425:sTRAILmR1–5
Cell line scFv425:
sTrailwt
scFv425:
sTrailmR1–5
P-value EGFR TRAIL-
R1
TRAIL-
R2
TR2/
TR1
TRAIL-
R4
TR1/
TR4
TR2/
TR4
OVCAR-3 57,1±8,6 78,8±5,0 0.0048 629 167,1 207,8 1,2 n.a. ––
A549 23,8±5,7 46,8±14,4 0.0106 1.755 69,7 151,5 2,2 8,3 8,4 18,2
HT-29 51,5±1,7 65,2±4,5 0.0468 317 8,1 35,1 4,3 5,2 1,6 6,8
HS683 69±0,9 76,87±2,1 0.0313 436 0,5 44,8 98,4 8,6 0,1 5,2
A431 21,3±8,1 45,6±10,1 0.0313 2727 4,7 7,8 1,7 n.a. ––
PC3-M 56,8±3,2 84,4±2,2 0.0003 34 1,9 45,3 23,4 6,86 0,3 6,6
RC21 57,6±18,0 66,8±13,6 n.s. 3.648 214,9 398,6 1,9 29,6 7,3 13,5
Sk-rc52 64,9±4,6 78,49±6,9 n.s. 1.263 12,1 133,0 11,0 13,5 0,9 9,9
A172 70,5±2,3 75,5±4,8 n.s. 182 0,6 112,2 178,2 3,6 0,2 31,2
WiDR 86,6±13,3 93±2,2 n.s. 256 17,8 56,3 3,2 1,9 9,5 29,9
The percentage of induction of apoptosis by scFv425:sTRAILwt and scFv425:sTRAILmR1–5 are the percentages obtained by treatment with
850 ng/ml. P-values were obtained using unpaired Student’s t-test. The MFI values of EGFR and TRAIL receptor expression are representatives
of three independent experiments
n.s. No significant difference, n.d. not determined
916 J Mol Med (2008) 86:909–924selective agonistic antibodies. A TRAIL-R1 agonistic
mAb was largely inactive on OVCAR-3 cells treated
with TRAIL-R1 siRNA (Fig. 5e), while a TRAIL-R2
agonistic mAb was largely inactive on OVCAR-3 cells
treated with TRAIL-R2 siRNA (Fig. 5f ) .T h u s ,t r e a t m e n t
with the respective TRAIL-R1 or TRAIL-R2 siRNA
indeed functionally downregulates the receptor. However,
scFv425:sTRAILmR1–5 potently induced apoptosis in
these cells irrespective of TRAIL-R1 or TRAIL-R2 down-
regulation (Fig. 5e and f), indicating that both receptors
can be activated by scFv425:sTRAILmR1–5. In addition,
the pro-apoptotic activity of scFv425:sTRAILwt was
markedly reduced compared to scFv425:sTRAILmR1–5
when TRAIL-R2 was knocked down, thus, confirming
previous reports that wild-type sTRAIL preferentially
signals via TRAIL-R2.
scFv425:sTRAILwt and scFv425:sTRAILmR1–5 activate
similar caspase signaling
The differential reliance on TRAIL-R1 or TRAIL-R2 for
induction of apoptosis by scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 after siRNA-mediated receptor
downregulation prompted us to assess whether the type
AB
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Fig. 3 scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 bind to
and activate apoptosis via
TRAIL-R1 and TRAIL-R2.
TRAIL receptor-specific bind-
ing of scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 was
assessed using a catching-type
ELISA with TRAIL-R1:Fc or
TRAIL-R2:Fc coated to the
bottom. a Increasing concentra-
tions of scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 were
incubated with TRAIL-R1:Fc
coated plates. b Increasing
concentrations of
scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 were
incubated with TRAIL-R2:Fc
coated plates. c Binding of
scFv425:sTRAILwt (850 ng/ml)
was competitively inhibited by
co-incubation with increasing
concentrations of TRAIL-R1:Fc
and TRAIL-R2:Fc. d Binding
of scFv425:sTRAILmR1–5
(850 ng/ml) was competitively
inhibited by co-incubation with
increasing concentrations of
TRAIL-R1:Fc and TRAIL-R2:
Fc. e Binding of
scFv425:sTRAILwt and
scFv425:sTRAILmR1–5
(600 ng/ml) was competitively
inhibited by co-incubation with
increasing concentrations of re-
combinant Flag-tagged
sTRAILwt. In all experiments,
TRAIL receptor-specific bind-
ing was determined by spectro-
photometry at OD450 as
described in “Materials and
methods”
J Mol Med (2008) 86:909–924 917of apoptosis induced by the two fusion proteins was similar
or divergent. Therefore, we treated RC21 and PC-3M cells
with scFv425:sTRAILwt and scFv425:sTRAILmR1–5 and
determined caspase activity at various time points. In both
RC21 and PC-3M cells, induction of apoptosis by scFv425:
sTRAILwt and scFv425:sTRAILmR1–5 was associated
with a similar activation profile for caspase-8 (Fig. 6a),
caspase-9 (Fig. 6b), and caspase-3 or caspase-7 (Fig. 6c).
As expected, caspase levels for scFv425:sTRAILmR1–5
were consistently higher in PC-3M cells (Fig. 6a, b, and
c). Subsequent inhibition of caspase-8, caspase-9, or
total caspases confirmed that scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 have a similar dependency on
caspases for execution of apoptosis (Fig. 6d). Interesting-
ly, immunoblot analysis of the caspase-8 inhibitor cFLIPL
revealed a striking difference between scFv425:sTRAILwt
and scFv425:sTRAILmR1–5. Cells treated with scFv425:
sTRAILmR1–5 displayed a total absence of cFLIPL,w h e r e a s
in scFv425:sTRAILwt treated cells, cFLIPL was markedly
upregulated compared to medium control (Fig. 6e and f).
However, this difference was found for both RC21 and
PC-3M cells, suggesting that it is not the underlying
reason for the differential activity of scFv425:sTRAILwt
and scFv425:sTRAILmR1–5.
The differential activity of scFv425:sTRAILwt
and scFv425:sTRAILmR1–5 is not due to NFκB signaling
Analysis of the pro-apoptotic signaling pathways by
scFv425:sTRAILwt and scFv425:sTRAILmR1–5 revealed
an intriguing difference in cFLIPL. Because this apoptotic
modulator has been linked to the NFκB pathway, we further
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B Fig. 4 Induction of apoptosis
by scFv425:sTRAILmR1–5 and
MOCK-scFv:sTRAILmR1–5i s
inhibited by TRAIL-R2 block-
ing mAb. RC21 cells
were treated with
a scFv425:sTRAILmR1–5
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mAbs. d RC21 cells were treated
with scFv425:sTRAILmR1–5
(500 ng/ml), scFv425:sTRAILwt
(500 ng/ml), or kTRAIL (50 ng/
ml) in the presence or absence of
TRAIL-R1:Fc or TRAIL-R2:Fc
(both 1 μg/ml). In all experi-
ments, apoptosis was assessed
by ΔΨ
918 J Mol Med (2008) 86:909–924analyzed the NFκB survival signaling as measured by
IL-8 production in response to scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 treatment in RC21 and PC-3M cells
(Fig. 7a). Contrary to expectations, scFv425:sTRAILmR1–5
consistently induced more NFκB signaling than
scFv425:sTRAILwt—also in A549, HT-29, and WiDr
cells (Fig. 7b). Interestingly, upon immunoblot analysis of
p100/p52 and p105/p50 a clear processing of p100 into
p52 was detected in scFv425:sTRAILwt but not in
scFv425:sTRAILmR1–5 treated cells in both RC21 and
PC-3M (Fig. 7c and d), indicating that the fusion proteins
activate different subunits of NFκB. To determine the
relevance of this observation for the differential apoptotic
activity of scFv425:sTRAILwt and scFv425:sTRAILmR1–5,
NFκB-signaling was inhibited using IKK inhibitor wedelo-
lactone. Unfortunately, cotreatment yielded a similar and
marginal increase in apoptosis for both fusion proteins
(Fig. 7e and f). Thus, although an intriguing difference in
NFκB signaling exists between scFv425:sTRAILwt and
scFv425:sTRAILmR1–5, this cannot account for the differ-
ential activity of these fusion proteins on PC-3M.
Discussion
Insight into the contribution of the respective agonistic
TRAIL receptors to induction of apoptosis by sTRAIL in
selected tumor types may help optimize TRAIL-based
therapeutic strategies. The role of TRAIL-R1 in TRAIL
signaling in particular is subject to debate. Therefore, we
here evaluated the pro-apoptotic activity of fusion protein
scFv425:sTRAILmR1–5, comprising EGFR-blocking anti-
body fragment scFv425 and the previously described
TRAIL-R1 selective sTRAIL mutant sTRAILmR1–5[ 25].
Fusion protein scFv425:sTRAILmR1–5 showed signifi-
cantly superior apoptotic activity compared to the
corresponding scFv425:sTRAILwt fusion protein on
~60% of the EGFR-positive solid tumor cell lines tested
and showed a nonsignificant trend to higher apoptotic
activity on the other cell lines. BothscFv425:sTRAILwtand
scFv425:sTRAILmR1–5 showed synergistic pro-apoptotic
activity upon cotreatment with cisplatin or the histone
deacetylase inhibitor VPA, but scFv425:sTRAILmR1–5
remained significantly more potent when compared to the
wild-type sTRAIL fusion protein. Induction of apoptosis by
scFv425:sTRAILmR1–5 as well as the synergistic induction
of apoptosis with VPA and cisplatin is dependent on binding
toEGFRbecauseco-incubationwithparentalEGFR-blocking
mAb 425 strongly inhibits apoptosis. Importantly, compared
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Fig. 5 scFv425:sTRAILwt and scFv425:sTRAILmR1–5 activate
apoptosis after siRNA-mediated downregulation of TRAIL-R1 or
TRAIL-R2. a OVCAR-3 cells were incubated with PE-conjugated
Goat-anti-Mouse polyclonal Ab (GaM-PE; solid fill), TRAIL-R1 mAb +
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after which TRAIL receptor expression was assessed by flow
cytometry as described in “Materials and methods.” b OVCAR-3
cells were treated with scFv425:sTRAILwt (850 ng/ml) or scFv425:
sTRAILmR1–5 (850 ng/ml). c. OVCAR-3 cells were treated for 72 h
with TRAIL-R1 siRNA and d. TRAIL-R2 siRNA, after which
expression of TRAIL receptors was assessed by incubating cells with
TRAIL-R1 mAb and TRAIL-R2 mAb. The depicted histograms are
representatives of three independent experiments. e After incubation
with TRAIL-R1 siRNA for 72 h, OVCAR-3 cells were treated with
scFv425:sTRAILwt, scFv425:sTRAILmR1–5, agonistic TRAIL-R1
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TRAIL-R2 mAb. In all experiments, apoptosis was assessed by ΔΨ
J Mol Med (2008) 86:909–924 919to a nontargeted MOCK-scFv:sTRAILmR1–5f u s i o np r o t e i n
directed at the B-cell marker CD20, scFv425:sTRAILmR1–5
showed superior apoptotic activity.
Mutant sTRAILmR1–5 was reported by MacFarlane et al.
to be selective for TRAIL-R1. This conclusion was mainly
based on the differential apoptotic activity of this mutant
towards Jurkat (TRAIL-R1
−/TRAIL-R2
+)a n dR a m o s
cells (TRAIL-R1
+/TRAIL-R2
+)[ 24]. However, our ex-
periments collectively demonstrate that sTRAILmR1–5
is actually not selective for TRAIL-R1. In ELISA experi-
ments, scFv425:sTRAILmR1–5 bound to TRAIL-R2:Fc
in a catching-type ELISA. Furthermore, binding of
scFv425:sTRAILmR1–5 to TRAIL-R1:Fc was competitively
inhibited by addition of soluble TRAIL-R2:Fc. Interestingly,
TRAIL-R1:Fc was superior to TRAIL-R2:Fc in inhibiting
scFv425:sTRAILmR1–5, whereas the reverse was true for
scFv425:sTRAILwt, indicating a reversal in affinity between
sTRAIL-wt and the sTRAILmR1–5d o m a i nf o rT R A I L - R 1
and TRAIL-R2. Of note, the only interaction that is being
investigated in these ELISAs is that of the sTRAIL domain
with TRAIL receptors. Thus, these experiments demonstrate
that the sTRAILmR1–5 domain in itself is capable of binding
to TRAIL-R2.
The binding of the sTRAILmR1–5 domain to TRAIL-
R2 also has functional implications because induction of
apoptosis by scFv425:sTRAILmR1–5 was markedly
inhibited by a TRAIL-R2 blocking antibody. In actual fact,
the TRAIL-R2 blocking mAb was more effective than the
TRAIL-R1 blocking mAb. Moreover, ~92% downregula-
tion of TRAIL-R1 by small inhibitory RNA did not
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Fig. 6 scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 activate
similar caspase signaling. Activi-
ty of a Caspase-8, b Caspase-9
and c Caspase-3 or Caspase-7
was assessed in PC-3M and
RC21 cells after incubation for 1,
2, 3, 4, 5, 6, or 16 h with either
scFv425:sTRAILwt (850 ng/ml)
or scFv425:sTRAILmR1–5
(850 ng/ml) d. PC-3M cells were
treated for 16 h with
scFv425:sTRAILwt (850 ng/ml)
or scFv425:sTRAILmR1–5
(850 ng/ml) in the
presence or absence of zIETD-
FMK (20 μM), zLEHD-FMK
(20 μM), or zVAD-FMK
(20 μM). Apoptosis was assessed
by ΔΨ. e RC21 and f PC-3M
cells were incubated for 6 h with
scFv425:sTRAILwt (850 ng/ml)
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absence of zVAD-FMK (20 μM).
Whole cell lysates were analyzed
for the presence of caspase-8 and
cFLIPL
920 J Mol Med (2008) 86:909–924abrogate the apoptotic activity of scFv425:sTRAILmR1–5.
Indeedsomeofthemoresensitivecelllinesactuallyhavevery
low TRAIL-R1 expression (Table 2). Collectively, these data
indicate that target antigen-bound scFv425:sTRAILmR1–5i s
capable of binding to and activating TRAIL-R2. Therefore,
our data also warrant a re-evaluation of the conclusion of
MacFarlane et al. that nontargeted sTRAILmR1–5i s
selective for TRAIL-R1.
Interestingly, induction of apoptosis by scFv425:
sTRAILmR1–5 fusion protein was more effectively
inhibited by TRAIL-R blocking mAbs than the induction
of apoptosis by scFv425:sTRAILwt or kTRAIL. These
experiments suggest that the wild-type sTRAIL domain has
a relatively higher affinity for its receptors and can, thus,
more efficiently compete with the TRAIL-R blocking mAbs
for binding to the receptors. Together, this also implies that,
while en route to the tumor, scFv425:sTRAILmR1–5w i l l
display a more transient binding to the ubiquitously ex-
pressed TRAIL receptors. As a result, tumor cell accretion is
expected to be more efficient for scFv425:sTRAILmR1–5
compared to scFv425:sTRAILwt.
Our experimental data regarding the activity of
scFv425:sTRAILmR1–5 also highlight an intriguing ques-
tion, namely: what is the molecular mechanism for the
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Fig. 7 The differential activity
of scFv425:sTRAILwt and
scFv425:sTRAILmR1–5 is not
due to NFκB signalling. a
RC21, PC-3M and b A549,
HT29, and WiDr cells were
incubated for 16 h with
scFv425:sTRAILwt (850 ng/ml)
or scFv425:sTRAILmR1–5
(850 ng/ml) in the presence or
absence of zVAD-FMK
(20 μM), after which, superna-
tant was analyzed for IL-8 lev-
els. c RC21 and d PC-3M cells
were incubated in the presence
or absence of zVAD-FMK
(20 μM). Whole cell lysates
were analyzed for the presence
of NFκB subunits p100/p52,
p105/p50, and p65. e RC21 and
f PC-3M cells were treated for
6 h with scFv425:sTRAILwt
(850 ng/ml) or
scFv425:sTRAILmR1–5
(850 ng/ml) in the presence of
IKK inhibitor wedelolactone.
Apoptosis was assessed by DY
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positive tumor cell lines as reported here and on primary
patient-derived B-cell chronic lymphoid leukemia (B-
CLL) cells as reported previously. First and foremost,
based on our experimental evidence, it is obvious that
both TRAIL-R1 and TRAIL-R2 signaling are an integral
part of the apoptotic activity of this mutant. However,
there is no obvious correlation between the apoptotic
activity of scFv425:sTRAILmR1–5 and the expression
levels of the respective TRAIL receptors, nor the ratios of
the various TRAIL receptors (TRAIL-R2/TRAIL-R1,
TRAIL-R1/TRAIL-R4, and TRAIL-R2/TRAIL-R4).
One possible explanation for our and MacFarlane’s
observations may be found in the incompletely character-
ized complexity of TRAIL receptor biology. Several groups
have found experimental evidence that TRAIL receptors
cannot only exist in a homotrimeric form but can also form
heterotrimeric complexes comprising TRAIL-R1 and
TRAIL-R2 monomers [28, 29]. As such, TRAIL-R1 or
TRAIL-R2 heterotrimers may represent nature’s strategy to
fine tune the apoptotic response to TRAIL.
It is tempting to speculate that sTRAILmR1–5, besides
activating homotrimeric TRAIL-R1, may be better able to
activate TRAIL-R1 or TRAIL-R2 heterotrimers than wild-
type sTRAIL. Such a differential capacity to activate
heterotrimers might explain the superior induction of apo-
ptosis by scFv425:sTRAILmR1–5 in a subset of cell lines.
This hypothesis is in line with most of our observations,
includingthefindingthatscFv425:sTRAILmR1–5isinactive
onA2780cellsthatonlyexpressTRAIL-R2(datanotshown),
while induction of apoptosis by scFv425:sTRAILmR1–5i s
potently inhibited by a TRAIL-R2 blocking antibody on
TRAIL-R1
+/TRAIL-R2
+ cells. Moreover, siRNA knockdown
of either TRAIL-R1 or TRAIL-R2 by >90% does not block
induction of apoptosis by scFv425:sTRAILmR1–5.
Further circumstantial evidence for heterotrimeric
TRAIL-R1 or TRAIL-R2 can be found in a recent report in
which it was shown that selective activation of either
TRAIL-R1 or TRAIL-R2 with receptor specific agonistic
mAbs in B-CLL cells is not as effective as sTRAIL-mediated
apoptosis of the same cells [30]. These results point to a
benefit of simultaneous triggering of both TRAIL receptors.
Interestingly, sTRAIL versions such as Apo2L or sTRAIL
(Genentech) that activate apoptosis predominantly through
TRAIL-R2 were less efficacious than those versions that
also signal apoptosis via TRAIL-R1, which is in agreement
with our finding that scFv425:sTRAILmR1–5 is more
active than scFv425:sTRAILwt.
An alternative or complementary hypothesis for the
enhanced activity of scFv425:sTRAILmR1–5m a yb e
found in the recently described potential for S-nitrosylation
of TRAIL-R1 and not TRAIL-R2 [31]. Tang et al. found
that treatment of OVCAR-3 cells with a nitric oxide donor
resulted in the S-nitrosylation of TRAIL-R1 at cysteine
residue 336, with a concomitant superior induction of
apoptosis by TRAIL. Therefore, the presence of S-nitro-
sylated TRAIL-R1 in certain cell lines, intrinsically subject
to higher nitric oxide stress, may account for the superior
apoptotic activity of scFv425:sTRAILmR1–5.
Importantly, the superior apoptotic activity of
scFv425:sTRAILmR1–5 on certain cell lines is not
related to Phosphoinositide 3-kinase signaling, C-Jun N-
terminal kinases signaling (data not shown), nor on
differential caspase signaling or NFκB signaling. How-
ever, independent of the differential apoptotic activity of
scFv425:sTRAILwt and scFv425:sTRAILmR1–5, we
observed an intriguing difference in the level of cFLIPL
in treated cells. Treatment with scFv425:sTRAILwt was
associated with an increased level of cFLIPL,w h e r e a s
scFv425:sTRAILmR1–5 treated cells lacked cFLIPL expres-
sion altogether. At the same time, scFv425:sTRAILmR1–5
treated cells showed increased levels of NFκB activation, as
judged by IL-8 production. Therefore, although cFLIPL has
been predominantly described as a constitutive activator of
NFκB signaling, our data actually highlight a potential
opposite correlation, with loss of cFLIPL occurring concur-
rently with higher NFκB activity. This finding is in
agreement with a previous report by Wajant et al. who also
demonstrated an inhibitory role of cFLIPL. A further
intriguing finding regarding the NFκB pathway is the
differential processing of the pro-units p100 into p52 by
scFv425:sTRAILwt but not by scFv425:sTRAILmR1–5.
Although puzzling, our data highlight the very complex
relationship between TRAIL receptor signaling and NFκB
activation.
Of note, mutant sTRAILmR1–5 is a derivative of
another designed TRAIL-R1 selective sTRAIL mutant,
sTRAILmR1–6, that was generated by Kelley et al. [23].
Based partly on mutant sTRAILmR1–6, Kelley et al.
ascribed a greater role for TRAIL-R2 in TRAIL-apoptotic
signaling in solid tumors. Because this mutant was later
found to be inactive and we here clearly demonstrate
TRAIL-R1 signaling in solid tumor cells, the conclusions
of Kelley et al. that TRAIL-R1 is not important in solid
tumors may need to be revised.
Although homotrimeric wild-type sTRAIL is widely
regarded as nontoxic toward normal human cells, an
important issue to consider in the use of mutated versions
of sTRAIL, such as sTRAILmR1–5, is the potential presence
of toxicity resulting from the incorporated amino acid
mutations. A future in depth toxicological evaluation in
primary human cells and in appropriate animal models will
be required to accurately assess the toxicity profile, and thus
the therapeutic potential, of scFv425:sTRAILmR1–5.
In conclusion, the EGFR-specific delivery of mutant
sTRAILmR1–5 results in superior apoptotic activity to-
922 J Mol Med (2008) 86:909–924wards EGFR-positive tumor cells. Further preclinical
development of scFv425:sTRAILmR1–5 appears warranted
to determine the therapeutic potential of this fusion protein
for the treatment of EGFR-positive tumors.
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